SCM
CCXI

Silvant Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Silvant Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,699
Closed -$292K – 338
2021
Q1 		$292K Hold
5,699
– – 0.05% 159
2020
Q4 		$353K Hold
5,699
– – 0.06% 151
2020
Q3 		$312K Buy
+5,699
New +$307K 0.06% 145

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Silvant Capital Management's CCXI Position: Q2 2021 in Review

Silvant Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2021, closing a stake of 5,699 shares — an estimated $292K sold.

Silvant Capital Management first reported a position in CCXI in Q3 2020 and held it in 3 quarters. The position peaked at $353K in Q4 2020. 146 funds tracked by Wall St. Rank hold CCXI as of Q2 2021.

  • Silvant Capital Management reported no remaining ChemoCentryx, Inc. position as of Q2 2021 after selling out during the quarter.
  • Silvant Capital Management sold 5,699 ChemoCentryx, Inc. shares in Q2 2021, an estimated $292K.
  • Silvant Capital Management first reported a position in ChemoCentryx, Inc. in Q3 2020 and held it in 3 quarters.
  • Silvant Capital Management's ChemoCentryx, Inc. position peaked at $353K in Q4 2020.
  • 146 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2021.

Based on Silvant Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.